AstraZeneca PLC (AZN)
USD 64.64
(-3.78%)
USD 64.64
(-3.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.57 Billion USD | 2.19% |
| 2022 | 28.2 Billion USD | 17.89% |
| 2021 | 23.92 Billion USD | 48.08% |
| 2020 | 16.15 Billion USD | -0.67% |
| 2019 | 16.26 Billion USD | 18.14% |
| 2018 | 13.76 Billion USD | -4.86% |
| 2017 | 14.47 Billion USD | 3.55% |
| 2016 | 13.97 Billion USD | -12.38% |
| 2015 | 15.94 Billion USD | -11.97% |
| 2014 | 18.11 Billion USD | 8.23% |
| 2013 | 16.73 Billion USD | 15.98% |
| 2012 | 14.43 Billion USD | -11.2% |
| 2011 | 16.25 Billion USD | 5.63% |
| 2010 | 15.38 Billion USD | -0.65% |
| 2009 | 15.48 Billion USD | 0.22% |
| 2008 | 15.45 Billion USD | 6.6% |
| 2007 | 14.49 Billion USD | 14.13% |
| 2006 | 12.7 Billion USD | 5.03% |
| 2005 | 12.09 Billion USD | 3.47% |
| 2004 | 11.68 Billion USD | 13.8% |
| 2003 | 10.26 Billion USD | 14.49% |
| 2002 | 8.96 Billion USD | -48.97% |
| 2001 | 17.57 Billion USD | 28.84% |
| 2000 | 13.64 Billion USD | 0.15% |
| 1999 | 13.62 Billion USD | 89.89% |
| 1998 | 7.17 Billion USD | 5.9% |
| 1997 | 6.77 Billion USD | -7.4% |
| 1996 | 7.31 Billion USD | 24.27% |
| 1995 | 5.88 Billion USD | 1.31% |
| 1994 | 5.81 Billion USD | 4.73% |
| 1993 | 5.54 Billion USD | 9.01% |
| 1992 | 5.09 Billion USD | -16.33% |
| 1991 | 6.08 Billion USD | 0.66% |
| 1990 | 6.04 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.95 Billion USD | 9.03% |
| 2024 Q1 | 6.29 Billion USD | -4.75% |
| 2023 Q3 | 7.44 Billion USD | 6.33% |
| 2023 Q4 | 7.71 Billion USD | 3.61% |
| 2023 FY | 28.82 Billion USD | 2.19% |
| 2023 Q1 | 6.66 Billion USD | -7.58% |
| 2023 Q2 | 7 Billion USD | 5.01% |
| 2022 Q4 | 7.21 Billion USD | 9.44% |
| 2022 Q2 | 7.23 Billion USD | 3.33% |
| 2022 FY | 28.2 Billion USD | 17.89% |
| 2022 Q3 | 6.59 Billion USD | -8.89% |
| 2022 Q1 | 7 Billion USD | -8.82% |
| 2021 Q4 | 7.67 Billion USD | 3.23% |
| 2021 FY | 23.92 Billion USD | 48.08% |
| 2021 Q1 | 3.56 Billion USD | -19.03% |
| 2021 Q2 | 4.9 Billion USD | 37.66% |
| 2021 Q3 | 7.43 Billion USD | 51.73% |
| 2020 Q2 | 4 Billion USD | 7.89% |
| 2020 FY | 16.15 Billion USD | -0.67% |
| 2020 Q1 | 3.71 Billion USD | -20.37% |
| 2020 Q3 | 3.88 Billion USD | -3.02% |
| 2020 Q4 | 4.39 Billion USD | 13.18% |
| 2019 Q1 | 3.26 Billion USD | -11.83% |
| 2019 FY | 16.26 Billion USD | 18.14% |
| 2019 Q4 | 4.66 Billion USD | 9.92% |
| 2019 Q3 | 4.24 Billion USD | -0.56% |
| 2019 Q2 | 4.26 Billion USD | 30.69% |
| 2018 FY | 13.76 Billion USD | -4.86% |
| 2018 Q1 | 3.34 Billion USD | -13.4% |
| 2018 Q2 | 3.38 Billion USD | 0.96% |
| 2018 Q3 | 3.33 Billion USD | -1.3% |
| 2018 Q4 | 3.7 Billion USD | 11.0% |
| 2017 Q3 | 3.83 Billion USD | 20.72% |
| 2017 FY | 14.47 Billion USD | 3.55% |
| 2017 Q4 | 3.86 Billion USD | 0.83% |
| 2017 Q2 | 3.17 Billion USD | -11.63% |
| 2017 Q1 | 3.59 Billion USD | 89.96% |
| 2016 Q4 | 1.89 Billion USD | -49.83% |
| 2016 FY | 13.97 Billion USD | -12.38% |
| 2016 Q2 | 4.23 Billion USD | 4.05% |
| 2016 Q1 | 4.07 Billion USD | 0.77% |
| 2016 Q3 | 3.77 Billion USD | -11.02% |
| 2015 Q3 | 3.73 Billion USD | -13.5% |
| 2015 Q2 | 4.31 Billion USD | 11.98% |
| 2015 FY | 15.94 Billion USD | -11.97% |
| 2015 Q4 | 4.04 Billion USD | 8.25% |
| 2015 Q1 | 3.85 Billion USD | -28.15% |
| 2014 Q2 | 4.03 Billion USD | -2.16% |
| 2014 Q3 | 4.58 Billion USD | 13.57% |
| 2014 FY | 18.11 Billion USD | 8.23% |
| 2014 Q1 | 4.12 Billion USD | -31.16% |
| 2014 Q4 | 5.36 Billion USD | 16.99% |
| 2013 Q3 | 3.3 Billion USD | -11.01% |
| 2013 Q2 | 3.71 Billion USD | -0.19% |
| 2013 FY | 16.73 Billion USD | 15.98% |
| 2013 Q1 | 3.72 Billion USD | -5.05% |
| 2013 Q4 | 5.99 Billion USD | 81.34% |
| 2012 Q4 | 3.92 Billion USD | 20.54% |
| 2012 Q3 | 3.25 Billion USD | -5.63% |
| 2012 Q1 | 3.81 Billion USD | -21.8% |
| 2012 FY | 14.43 Billion USD | -11.2% |
| 2012 Q2 | 3.44 Billion USD | -9.65% |
| 2011 Q3 | 2.35 Billion USD | -40.8% |
| 2011 FY | 16.25 Billion USD | 5.63% |
| 2011 Q4 | 4.87 Billion USD | 106.83% |
| 2011 Q2 | 3.98 Billion USD | 12.13% |
| 2011 Q1 | 3.55 Billion USD | -31.15% |
| 2010 Q4 | 5.15 Billion USD | 30.02% |
| 2010 FY | 15.38 Billion USD | -0.65% |
| 2010 Q1 | 3.27 Billion USD | -24.04% |
| 2010 Q3 | 3.96 Billion USD | 7.48% |
| 2010 Q2 | 3.69 Billion USD | 12.6% |
| 2009 FY | 15.48 Billion USD | 0.22% |
| 2009 Q3 | 3.79 Billion USD | 4.09% |
| 2009 Q4 | 4.31 Billion USD | 13.84% |
| 2009 Q1 | 3.15 Billion USD | -29.04% |
| 2009 Q2 | 3.64 Billion USD | 15.47% |
| 2008 Q1 | 3.83 Billion USD | -18.52% |
| 2008 Q3 | 3.65 Billion USD | -6.68% |
| 2008 Q4 | 4.44 Billion USD | 21.51% |
| 2008 Q2 | 3.92 Billion USD | 2.3% |
| 2008 FY | 15.45 Billion USD | 6.6% |
| 2007 Q3 | 3.57 Billion USD | 3.53% |
| 2007 Q4 | 4.7 Billion USD | 31.51% |
| 2007 Q2 | 3.45 Billion USD | 4.38% |
| 2007 FY | 14.49 Billion USD | 14.13% |
| 2007 Q1 | 3.31 Billion USD | -7.36% |
| 2006 Q3 | 3.07 Billion USD | -1.03% |
| 2006 Q2 | 3.1 Billion USD | 5.08% |
| 2006 Q1 | 2.95 Billion USD | -9.47% |
| 2006 FY | 12.7 Billion USD | 5.03% |
| 2006 Q4 | 3.57 Billion USD | 16.35% |
| 2005 Q2 | 3.1 Billion USD | 7.67% |
| 2005 Q4 | 3.26 Billion USD | 14.5% |
| 2005 Q3 | 2.84 Billion USD | -8.13% |
| 2005 Q1 | 2.88 Billion USD | -60.57% |
| 2005 FY | 12.09 Billion USD | 3.47% |
| 2004 Q2 | 2.98 Billion USD | 4.22% |
| 2004 Q4 | 7.3 Billion USD | 160.24% |
| 2004 Q3 | 2.8 Billion USD | -5.96% |
| 2004 FY | 11.68 Billion USD | 13.8% |
| 2004 Q1 | 2.86 Billion USD | -3.54% |
| 2003 Q1 | 2.33 Billion USD | -20.63% |
| 2003 FY | 10.26 Billion USD | 14.49% |
| 2003 Q4 | 2.96 Billion USD | 18.11% |
| 2003 Q3 | 2.51 Billion USD | 2.41% |
| 2003 Q2 | 2.45 Billion USD | 5.26% |
| 2002 FY | 8.96 Billion USD | -48.97% |
| 2002 Q4 | 2.93 Billion USD | 32.92% |
| 2002 Q2 | 2.18 Billion USD | 11.74% |
| 2002 Q1 | 1.95 Billion USD | -83.29% |
| 2002 Q3 | 2.21 Billion USD | 1.02% |
| 2001 Q2 | 2.04 Billion USD | 8.83% |
| 2001 Q4 | 11.71 Billion USD | 526.13% |
| 2001 Q3 | 1.87 Billion USD | -8.6% |
| 2001 FY | 17.57 Billion USD | 28.84% |
| 2001 Q1 | 1.88 Billion USD | -75.98% |
| 2000 Q1 | 1.92 Billion USD | -72.09% |
| 2000 Q3 | 1.9 Billion USD | -4.38% |
| 2000 Q4 | 7.82 Billion USD | 311.88% |
| 2000 FY | 13.64 Billion USD | 0.15% |
| 2000 Q2 | 1.98 Billion USD | 3.3% |
| 1999 Q1 | - USD | 100.0% |
| 1999 FY | 13.62 Billion USD | 89.89% |
| 1999 Q2 | 2.3 Billion USD | 0.0% |
| 1999 Q3 | 2.11 Billion USD | -8.11% |
| 1999 Q4 | 6.89 Billion USD | 225.53% |
| 1998 FY | 7.17 Billion USD | 5.9% |
| 1998 Q3 | - USD | -100.0% |
| 1998 Q1 | - USD | 100.0% |
| 1998 Q4 | -7.17 Billion USD | 0.0% |
| 1998 Q2 | 1.04 Billion USD | 0.0% |
| 1997 Q4 | -6.77 Billion USD | 0.0% |
| 1997 Q1 | - USD | 100.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 6.77 Billion USD | -7.4% |
| 1997 Q2 | - USD | 0.0% |
| 1996 FY | 7.31 Billion USD | 24.27% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | -7.31 Billion USD | 0.0% |
| 1996 Q1 | - USD | 100.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q1 | - USD | 100.0% |
| 1995 FY | 5.88 Billion USD | 1.31% |
| 1995 Q4 | -5.88 Billion USD | 0.0% |
| 1995 Q2 | 690.4 Million USD | 0.0% |
| 1994 Q1 | - USD | 100.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q4 | -5.81 Billion USD | 0.0% |
| 1994 FY | 5.81 Billion USD | 4.73% |
| 1994 Q3 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | -5.54 Billion USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | 5.54 Billion USD | 9.01% |
| 1992 FY | 5.09 Billion USD | -16.33% |
| 1991 FY | 6.08 Billion USD | 0.66% |
| 1990 FY | 6.04 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amgen Inc. | 11.87 Billion USD | -149.015% |
| Biogen Inc. | 5.2 Billion USD | -468.272% |
| Gilead Sciences, Inc. | 13.01 Billion USD | -127.296% |
| MIRA Pharmaceuticals, Inc. | 8.52 Million USD | -346813.283% |
| Scilex Holding Company | 136.49 Million USD | -21569.976% |
| Scilex Holding Company | 136.49 Million USD | -21569.976% |